How Muscle Damage Markers Change With Age

Muscle damage markers are circulating and tissue-derived analytes used in research to quantify the mechanical and metabolic disruption that follows eccentric or high-intensity exercise. The most frequently reported in the studies summarised here are creatine kinase (CK) and lactate dehydrogenase (LDH), both intracellular enzymes released into blood when sarcolemmal integrity is compromised; they are typically reported alongside oxidative-stress analytes such as malondialdehyde (MDA), 8-hydroxy-2'-deoxyguanosine (8-OHdG), F2-isoprostanes, the glutathione ratio (GSH/GSSG), and antioxidant enzyme activities (SOD, CAT, GPx), and alongside inflammatory markers including hsCRP, MCP-1 and IL-6 [1]. CK and LDH are proteins rather than small molecules, so no single sequence, formula or molecular weight is given in the evidence block; the identifiers supplied are the assay names and the sampling timepoints at which they are measured.

The mechanistic work in this area centres on the antioxidant-response and redox-signalling axis, in which dietary antioxidants and nicotinamide-adenine-dinucleotide (NAD+) precursor supplementation are studied for their effects on the oxidative and inflammatory cascades that accompany exercise-induced muscle damage [1][2].

Research Studies

Creatine kinase and lactate dehydrogenase as age-relevant muscle damage markers in exercise trials

CK and LDH are the two muscle damage markers named explicitly in the pterostilbene cocrystal trial protocol, where they are listed among the secondary outcomes measured after a high-intensity exercise session [1]. The same trial measures MDA as its primary outcome, with 8-OHdG, F2-isoprostanes, FRAP, GSH/GSSG, SOD, CAT, GPx, hsCRP, MCP-1, IL-6, cortisol, creatinine and gene expression patterns as additional secondary endpoints [1]. Because the protocol captures this panel in a single sampling frame, it provides a template for asking whether the CK and LDH response to a standardised exercise bout differs between younger and older participants. The evidence block does not report age-stratified results, so any statement about the direction or magnitude of an age effect on CK or LDH would be unsupported by the material available here.

Astaxanthin and muscle damage markers after eccentric arm exercise in adult males

Astaxanthin (AX) is described in the evidence as a potent antioxidant and anti-inflammatory carotenoid, and prior research examining whether AX could counteract exercise-induced muscle damage and improve exercise capacity is reported to have produced inconsistent results [2]. To address that inconsistency, one study supplemented twenty-four males for four weeks, randomly assigned to AX12 (12 mg/day; n=8), AX36 (36 mg/day; n=9), or placebo (PLC; n=7), and collected blood samples at rest, immediately after, and at 2, 24, 48 and 72 hours following eccentric arm exercise [2]. The stated aims were to explore the impact of AX on muscle damage markers, total antioxidant status, and a subjective marker of muscle pain [2]. The population is adult males; the evidence block does not report the age range, and it does not report outcome values, so no dose-response or age-related conclusion can be drawn from it here.

Chickpea protein hydrolysate and muscle damage markers during a football tournament

A randomised, placebo-controlled crossover study evaluated a beverage containing chickpea protein hydrolysate in football players, with participants receiving the active beverage and a matched protein-containing placebo during two four-week intervention periods separated by a two-week washout [3]. The assessed domains included biochemical safety parameters, antioxidant status, inflammatory biomarkers, lipid profile, lipid peroxidation, muscle damage markers, dietary intake and body composition [3]. This design is relevant to age-related questions because tournament schedules impose repeated bouts of exercise within a short window, and repeated-bout effects are a recognised confounder in muscle damage marker research. As with the other entries, the evidence block does not provide age-stratified data or numerical outcomes.

Pterostilbene cocrystal, silybin and nicotinamide riboside in exercise-induced oxidative stress

The combination product ccPT-SIL-NR contains pterostilbene (ccPT), silybin (SIL) and nicotinamide riboside (NR) [1]. The primary objective of the registered study is to assess changes in blood MDA levels after a high-intensity exercise session, with the secondary panel covering oxidative DNA damage, lipid peroxidation, total antioxidant capacity, glutathione ratio, antioxidant enzyme activity, inflammatory markers, muscle damage markers, cortisol, renal function and gene expression [1]. The inclusion of both oxidative and muscle damage readouts in one protocol makes this study a useful reference point for research asking whether redox status and sarcolemmal leakage markers move together or independently across age groups. The evidence block does not state participant ages or results.

Comparing the marker panels used across the three research models

The table below sets out which muscle damage and related markers each evidence entry reports, and in which population or model the measurement was made. It is a comparison of study designs, not of outcomes.

Sampling timepoints and why they matter for age comparisons

The astaxanthin study collected blood at rest, immediately after exercise, and at 2, 24, 48 and 72 hours post-exercise [2]. This six-point schedule is the kind of design needed to distinguish peak CK or LDH appearance from clearance, and peak timing is one of the parameters most plausibly affected by age-related changes in muscle mass, perfusion and repair capacity. The evidence block does not report peak values, clearance rates or age comparisons, so the timepoint structure can be described but not interpreted.

Where the evidence is limited to protocol-level information

All three entries in the evidence block are registry records describing planned or conducted studies rather than full reports of results [1][2][3]. None of them supplies numerical outcome data, effect sizes, confidence intervals or age-stratified analyses. No animal-only or in vitro data are provided in the evidence block for these compounds, so no such findings are described here. Any claim that a specific marker rises, falls or remains unchanged with age, or that any of these interventions modifies that trajectory, would go beyond what the available material supports.

Marker selection in ageing research: practical considerations from the protocols

Across the three protocols, the recurring core panel is CK and LDH for muscle damage, MDA and F2-isoprostanes for lipid peroxidation, 8-OHdG for oxidative DNA damage, GSH/GSSG and FRAP for redox balance, SOD, CAT and GPx for enzymatic antioxidant capacity, and hsCRP, MCP-1 and IL-6 for inflammation [1][2][3]. Because these analytes are influenced by training status, dietary intake and body composition, the chickpea protein hydrolysate protocol explicitly assessed dietary intake and body composition alongside the biochemical markers [3]. Researchers designing age-comparative work would need to control for the same variables, since the evidence block gives no indication that any of the three studies stratified or matched participants by age.

If you are reading this for personal health reasons

The compounds discussed here are supplied for laboratory research use only, and nothing on this page is medical or dosing guidance. We do not provide dosing information, and we cannot advise anyone on whether a compound is appropriate for them. Anyone considering a compound for their own use should speak to a licensed clinician.

Sources

• [1] Effect of the Combination of Pterostilbene Cocrystal With Silybin and Nicotinamide Riboside on Exercise-Induced Oxidative Stress — https://clinicaltrials.gov/study/NCT07024966
• [2] Effects of Astaxanthin Supplementation — https://clinicaltrials.gov/study/NCT06511960
• [3] Effect of Chickpea Protein Hydrolysate Supplementation on Muscle Damage and Inflammatory Plasma Markers During a Football Tournament: A Randomized, Placebo-Controlled Crossover Trial — https://clinicaltrials.gov/study/NCT07765719